[Federal Register Volume 69, Number 147 (Monday, August 2, 2004)]
[Notices]
[Page 46171]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-17465]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Methods and Compositions 
for the Promotion of Hair Growth Utilizing Actin Binding Peptides

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
part 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Patent Application Serial No. 60/351,386 (re-filed), PCT Patent 
Application Serial No. PCT/US03/01973, filed January 22, 2003 (DHHS 
Ref. E-053-2002/0-PCT-02), entitled ``Methods and Compositions for the 
Promotion of Hair Growth Utilizing Actin Binding Peptides'' to Panacea 
Biotec Ltd., which has offices in New Delhi, India. The patent rights 
in these inventions have been assigned to the United States of America.
    The prospective exclusive license territory may be limited to 
India, Sri Lanka, Bangladesh, Pakistan, Nepal, Malaysia, Thailand, 
Indonesia, Singapore and the Philippines, and the field of use may be 
limited to the use of actin binding proteins for the development of a 
topical hydrogel treatment for alopecia to promote hair growth (This 
notice modifies a previous Federal Register notice published in 69 FR 
13859, March 24, 2004).

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 1, 2004 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jesse S. Kindra, J.D., M.S., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; telephone: (301) 435-5559; facsimile: (301) 402-0220; e-
mail: [email protected].

SUPPLEMENTARY INFORMATION: The technology describes methods and 
compositions for treating a subject (human or animal) suffering from 
hair loss. More specifically, the technology relates to the discovery 
that actin binding peptides promote hair growth. In one example, the 
technology describes the exogenous delivery of a seven amino acid 
peptide of Thymosin-[beta]4 to promote hair growth.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: July 23, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-17465 Filed 7-30-04; 8:45 am]
BILLING CODE 4140-01-P